

Christopher

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4645136/publications.pdf>

Version: 2024-02-01

91
papers

2,159
citations

236833

25
h-index

276775

41
g-index

93
all docs

93
docs citations

93
times ranked

2344
citing authors

#	ARTICLE	IF	CITATIONS
1	Postoperative Complications and Mortality Following Colectomy for Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 972-980.	2.4	154
2	Clinical, endoscopic and radiographic outcomes with ustekinumab in medically refractory Crohn's disease: real world experience from a multicentre cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1232-1243.	1.9	141
3	Surgical Rates for Crohn's Disease are Decreasing: A Population-Based Time Trend Analysis and Validation Study. <i>American Journal of Gastroenterology</i> , 2017, 112, 1840-1848.	0.2	140
4	Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 833-839.	0.9	94
5	Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 5-23.	1.9	66
6	Anti-TNF Therapy Within 2 Years of Crohn's Disease Diagnosis Improves Patient Outcomes. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 870-879.	0.9	63
7	An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical Trials. <i>Gastroenterology</i> , 2021, 160, 2291-2302.	0.6	57
8	Innovations in Oral Therapies for Inflammatory Bowel Disease. <i>Drugs</i> , 2019, 79, 1321-1335.	4.9	51
9	Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 977-986.	1.9	47
10	Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 637-647.e13.	2.4	44
11	Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: A real life cohort study. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1454-1463.	0.6	43
12	Standardisation of intestinal ultrasound scoring in clinical trials for luminal Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 873-886.	1.9	43
13	Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 675-682.	1.1	41
14	Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn's Disease: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1407-1419.e22.	2.4	41
15	Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 1044-1055.	1.9	40
16	Epidemiologic Burden and Treatment of Chronic Symptomatic Functional Bowel Disorders in the United States: A Nationwide Analysis. <i>Gastroenterology</i> , 2021, 160, 88-98.e4.	0.6	37
17	Noninvasive Fecal Immunochemical Testing and Fecal Calprotectin Predict Mucosal Healing in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1643-1649.	0.9	36
18	Development of a core outcome set for clinical trials in inflammatory bowel disease: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. <i>BMJ Open</i> , 2017, 7, e016146.	0.8	35

#	ARTICLE	IF	CITATIONS
19	Preoperative Ustekinumab Treatment Is Not Associated With Increased Postoperative Complications in Crohn's Disease: A Canadian Multi-Centre Observational Cohort Study. <i>Journal of the Canadian Association of Gastroenterology</i> , 2018, 1, 115-123.	0.1	34
20	Heterogeneity in Clinical, Endoscopic, and Histologic Outcome Measures and Placebo Response Rates in Clinical Trials of Eosinophilic Esophagitis: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1714-1729.e3.	2.4	33
21	Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1047-1066.	1.9	33
22	Clinical utility of ustekinumab in Crohn's disease. <i>Journal of Inflammation Research</i> , 2018, Volume 11, 35-47.	1.6	32
23	Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1578-1596.	1.9	31
24	Inflammatory bowel disease patients who leave hospital against medical advice: Predictors and temporal trends. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 845-851.	0.9	29
25	CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2022, 163, 950-964.	0.6	29
26	Varicella zoster meningitis complicating combined anti-tumor necrosis factor and corticosteroid therapy in Crohn's disease. <i>World Journal of Gastroenterology</i> , 2013, 19, 3347.	1.4	28
27	IL12/23 or selective IL23 inhibition for the management of moderate-to-severe Crohn's disease?. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2019, 38-39, 101604.	1.0	28
28	Trends in U.S. Health Care Spending on Inflammatory Bowel Diseases, 1996-2016. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 364-372.	0.9	28
29	Assessing National Trends and Disparities in Ambulatory, Emergency Department, and Inpatient Visits for Inflammatory Bowel Disease in the United States (2005-2016). <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2500-2509.e1.	2.4	27
30	Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 435-445.	1.9	26
31	Systematic review: medical therapy for fibrostenosing Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1233-1246.	1.9	26
32	Adverse Events and Nocebo Effects in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1201-1216.	0.6	25
33	Epidemiology and Natural History of Perianal Crohn's Disease: A Systematic Review and Meta-Analysis of Population-Based Cohorts. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1477-1484.	0.9	23
34	Discordance Between Patient-Reported Outcomes and Mucosal Inflammation in Patients With Mild to Moderate Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1760-1768.e1.	2.4	22
35	Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease. <i>Drugs</i> , 2021, 81, 333-347.	4.9	22
36	Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2016, 2016, 1-9.	0.8	20

#	ARTICLE	IF	CITATIONS
37	Patient preferences for maintenance therapy in Crohn's disease: A discrete-choice experiment. <i>PLoS ONE</i> , 2020, 15, e0227635.	1.1	20
38	Investigational drugs in phase I and phase II clinical trials targeting interleukin 23 (IL23) for the treatment of Crohn's disease. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 649-660.	1.9	19
39	What is the role of C-reactive protein and fecal calprotectin in evaluating Crohn's disease activity?. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2019, 38-39, 101602.	1.0	19
40	An expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 784-793.	1.9	18
41	Reliability and responsiveness of endoscopic disease activity assessment in eosinophilic esophagitis. <i>Gastrointestinal Endoscopy</i> , 2022, 95, 1126-1137.e2.	0.5	18
42	Reliability of Endoscopic Evaluation of Postoperative Recurrent Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2139-2141.e2.	2.4	17
43	Factors Associated With Geographic Disparities in Gastrointestinal Cancer Mortality in the United States. <i>Gastroenterology</i> , 2022, 163, 437-448.e1.	0.6	16
44	Concomitant Use of Aminosaliculates Is Not Associated With Improved Outcomes in Patients With Ulcerative Colitis Escalated to Vedolizumab. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2374-2376.e2.	2.4	15
45	Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score. <i>Hepatology</i> , 2022, 76, 1150-1163.	3.6	15
46	Early Initiation of Tumor Necrosis Factor Antagonist-Based Therapy for Patients With Crohn's Disease Reduces Costs Compared With Late Initiation. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1515-1524.e4.	2.4	14
47	Corticosteroid-Free Remission vs Overall Remission in Clinical Trials of Moderate-to-Severe Ulcerative Colitis and Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 515-523.	0.9	14
48	The Argument Against a Biosimilar Switch Policy for Infliximab in Patients with Inflammatory Bowel Disease Living in Alberta. <i>Journal of the Canadian Association of Gastroenterology</i> , 2020, 3, 234-242.	0.1	14
49	Responsiveness of a Histologic Scoring System Compared With Peak Eosinophil Count in Eosinophilic Esophagitis. <i>American Journal of Gastroenterology</i> , 2022, 117, 264-271.	0.2	13
50	An expert consensus to standardise clinical, endoscopic and histologic items and inclusion and outcome criteria for evaluation of pouchitis disease activity in clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1108-1117.	1.9	13
51	Systematic review with meta-analysis: prevalence, risk factors and costs of aminosalicilate use in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 114-126.	1.9	12
52	Physicians' Perspectives on Cost, Safety, and Perceived Efficacy Determine Aminosalicilate Use in Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2555-2563.	1.1	12
53	Reduction in surgical stoma rates in Crohn's disease: a population-based time trend analysis. <i>Colorectal Disease</i> , 2019, 21, 1279-1287.	0.7	12
54	Targeting anti-fibrotic pathways in Crohn's disease - The final frontier?. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2019, 38-39, 101603.	1.0	12

#	ARTICLE	IF	CITATIONS
55	Antibody response to SARS-CoV-2 among individuals with IBD diminishes over time: a serosurveillance cohort study. <i>Gut</i> , 2022, 71, 1229-1231.	6.1	12
56	Serological responses to three doses of SARS-CoV-2 vaccination in inflammatory bowel disease. <i>Gut</i> , 2023, 72, 802-804.	6.1	12
57	Development of a Core Outcome Set for Therapeutic Studies in Eosinophilic Esophagitis (COREOS): An International Multidisciplinary Consensus. <i>Gastroenterology</i> , 2021, 161, 748-755.	0.6	11
58	Multimodal Brain MRI of Deep Gray Matter Changes Associated With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 405-416.	0.9	11
59	Improving Clinical Trial Efficiency in Gastroenterology. <i>Gastroenterology</i> , 2019, 157, 892-893.	0.6	10
60	The Relationship Between Endoscopic and Clinical Recurrence in Postoperative Crohn's Disease: A Systematic Review and Meta-analysis. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 490-499.	0.6	10
61	Colonic Dieulafoy's Lesion: A Rare Cause of Lower Gastrointestinal Hemorrhage and Review of Endoscopic Management. <i>Case Reports in Gastrointestinal Medicine</i> , 2014, 2014, 1-4.	0.2	9
62	Systematic Review and Meta-Analysis: Clinical, Endoscopic, Histological and Safety Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 224-243.	0.6	9
63	Clinical, Endoscopic, and Safety Placebo Rates in Induction and Maintenance Trials of Crohn's Disease: Meta-Analysis of Randomised Controlled Trials. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 717-736.	0.6	9
64	Recommendations for standardizing biopsy acquisition and histological assessment of immune checkpoint inhibitor-associated colitis. , 2022, 10, e004560.		9
65	Identifying Outcomes in Clinical Trials of Fistulizing Crohn's Disease for the Development of a Core Outcome Set. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1904-1908.	2.4	8
66	Frequency of Opioid Prescription at Emergency Department Discharge in Patients with Inflammatory Bowel Disease: A Nationwide Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2064-2071.e1.	2.4	8
67	Impact of Drug Approval Pathways for Paediatric Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 331-335.	0.6	8
68	Teduglutide in Patients With Active Crohn's Disease and Short Bowel Syndrome. <i>Inflammatory Bowel Diseases</i> , 2019, 25, e109-e109.	0.9	7
69	Physical Activity in Patients With Inflammatory Bowel Disease: A Narrative Review. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1100-1111.	0.9	7
70	Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2016, 2016, 1-11.	0.8	6
71	Vedolizumab Induced Clinical, Endoscopic, and Histological Improvement in Common Variable Immunodeficiency Disease-associated Intestinal Enteropathy. <i>Inflammatory Bowel Diseases</i> , 2020, 26, e22-e23.	0.9	6
72	Systematic review: disease activity indices for immune checkpoint inhibitor-associated enterocolitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 178-190.	1.9	6

#	ARTICLE	IF	CITATIONS
73	Review article: therapeutic targets for the pharmacologic management of coeliac disease—the future beyond a gluten-free diet. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1277-1296.	1.9	6
74	Recommendations for Standardizing Clinical Trial Design and Endoscopic Assessment in Postoperative Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1321-1331.	0.9	5
75	Is there room for immunomodulators in ulcerative colitis?. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 379-390.	1.4	4
76	Pharmacological Interventions for the Prevention and Treatment of Immune Checkpoint Inhibitor-Associated Enterocolitis: A Systematic Review. <i>Digestive Diseases and Sciences</i> , 2022, 67, 1128-1155.	1.1	4
77	Modeling Endoscopic Improvement after Induction Treatment With Mesalamine in Patients With Mild-to-Moderate Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 447-454.e1.	2.4	4
78	Design of Clinical Trials for Mild to Moderate Ulcerative Colitis. <i>Gastroenterology</i> , 2022, 162, 1005-1018.	0.6	4
79	Underrepresentation of Minorities and Lack of Race Reporting in Ulcerative Colitis Drug Development Clinical Trials. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1293-1295.	0.9	4
80	The Clinical Significance of Eosinophils in Ulcerative Colitis: A Systematic Review. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1321-1334.	0.6	4
81	Safety of Combination Biologic and Antirejection Therapy Post-Liver Transplantation in Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 26, 949-959.	0.9	3
82	Systematic review with meta-analysis: high prevalence and cost of continued aminosalicylate use in patients with ulcerative colitis escalated to immunosuppressive and biological therapies. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 364-374.	1.9	3
83	Identifying Outcomes in Clinical Trials of Pouchitis for the Development of a Core Outcome Set. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1637-1640.	2.4	3
84	Clinical Course and Treatment Implications of Combination Immune Checkpoint Inhibitor-Mediated Hepatitis: A Multicentre Cohort. <i>Journal of the Canadian Association of Gastroenterology</i> , 2022, 5, 39-47.	0.1	3
85	Population-based Trends in Healthcare Utilization and National Healthcare Spending on Pancreatitis in North America. <i>Gastroenterology</i> , 2021, 161, 1698-1701.e5.	0.6	3
86	Novel Therapeutics for the Treatment of IBD: Current Status and Future Directions. <i>Current Treatment Options in Gastroenterology</i> , 2020, 18, 442-461.	0.3	2
87	Impact of COVID-19 on Inflammatory Bowel Disease Clinical Trial Recruitment: A Global Survey of Principal Investigators. <i>Inflammatory Bowel Diseases</i> , 2021, 27, e98-e98.	0.9	2
88	To Stop or Not to Stop? Predicting Relapse After Anti-TNF Cessation in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1668-1670.	2.4	1
89	Methods for handling missing segments in Crohn's disease clinical trials: analysis from the EXTEND trial. <i>Gut</i> , 2022, 71, 447-448.	6.1	1
90	A Summary of the Meetings of the Development of a Core Outcome Set for Therapeutic Studies in Eosinophilic Esophagitis (COREOS) International Multidisciplinary Consensus. <i>Gastroenterology</i> , 2021, 161, 778-784.	0.6	0

#	ARTICLE	IF	CITATIONS
91	Editorial: some of the obstacles in managing mood disorders in <scp>IBD</scp>. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1054-1055.	1.9	0